Pfizer has chosen the CROs ICON Clinical Research and Parexel International as its two preferred drug development partners, as it seeks to streamline its R&D dollar commitment.
Pfizer believes that by changing its approach to R&D it will "sharpen research focus, deliver differentiated innovation, and create a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?